Medigene & EpimAb ink co-development partnership for TCR-guided T Cell Engagers to treat of immune-related disorders
Medigene AG and EpimAb Biotherapeutics, Inc. (EpimAb), announced that the companies have entered a strategic co-development agreement to research and develop off-the-shelf T cell receptor (TCR)-guided T Cell Engagers (TCR-TCEs) for the treatment of immune- …